Interní Med. 2010; 12(4): 223-224

Rosiglitazone in the treatment of diabetes in 2010, what’s new?

prof.MUDr.Martin Haluzík, DrSc.
III. interní klinika 1. LF UK a VFN, Praha

Glitazones are antidiabetic drugs acting through the stimulation of nuclear PPAR (peroxisome proliferator activated receptors) receptors.

Due to pleiotropic effects of PPAR activation glitazones not only improve blood glucose and insulin resistance but also exert

antiinflammatory, blood pressure lowering and numerous other positive effects. In addition to benefitial effects of glitazones possible

cardiovascular side effects in patients with coronary heart disease are discussed especially in connection with rosiglitazone. The aim of

this article is to summarize the results of recent trials with rosiglitazone in patients with cardiovascular complications. From the cardiovascular

safety point of view strict adherence to contraindications of glitazones administration is necessary (especially presence of heart

failure is important contraindication). The results of recent studies demonstrate that addition of glitazones to combined antidiabetic

treatment can have very positive effects even in patients with increased cardiovascular risk.

Keywords: glitazones, rosiglitazone, PPAR receptors, cardiovascular complications

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haluzík M. Rosiglitazone in the treatment of diabetes in 2010, what’s new? Interní Med. 2010;12(4):223-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Haluzík M, Svačina S. Metabolický syndrom a nukleární receptory PPAR. Grada Publishing, Praha 2005.
    2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. Go to original source... Go to PubMed...
    3. FDA http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf.
    4. Piťhová P. Rosiglitazon - molekula z nebe, či pekla? Lékařské listy, 2008: 26-28.
    5. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105. Go to original source... Go to PubMed...
    6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. Go to original source... Go to PubMed...
    7. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38. Go to original source... Go to PubMed...
    8. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J.
    9. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
    10. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515. Go to original source... Go to PubMed...
    11. Gerstein HC, Ratner RE, Cannon CP, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 121: 1176-1187. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.